Dextera Surgical Inc.’s MicroCutter 5/80 Enables Shorter Hospital Stays Through Less Invasive Lobectomy

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dextera Surgical Inc. (Nasdaq:DXTR), manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced that Marco Nardini, M.D., from James Cook University Hospital in Middlesbrough, UK, presented the latest data on the results of 82 patients undergoing Microlobectomy. The data demonstrated that for Microlobectomy procedures, the median hospital stay is reduced by at least two days when compared to traditional open lobectomy procedures, with over 20 percent of patients going home the day after surgery.

“The interest in the presentation at the meeting reflects the global interest in technologies like the MicroCutter 5/80 that enable less invasive approaches to lobectomy that may accelerate the adoption of video-assisted thoracic surgery (VATS) techniques and other surgical procedures.”

“The Microlobectomy procedure, enabled by the MicroCutter 5/80 surgical stapler, due to the slim profile of the five-millimeter diameter with 80 degrees of articulation, reduces postoperative pain and complications compared to traditional open procedures and overall, improves a patient’s recovery after a major lung resection,” commented Dr. Nardini. “These data further support what surgeons around the world are experiencing when performing the Microlobectomy – that the less invasive nature of this procedure shortens hospital stays when compared to a traditional open lobectomy, with 20.7% of patients able to return home within 24 hours.”

For the 82 patients undergoing a Microlobectomy, the median length of hospital stay was three days, with 17 patients (20.7%) discharged the day after surgery and an additional 14 patients (17%) discharged two days after surgery. Data were presented at the Scandinavian Society for Research in Cardiothoracic Surgery 2017 held in Geilo, Norway.

Liam Burns, vice president worldwide sales and marketing of Dextera Surgical, commented, “The interest in the presentation at the meeting reflects the global interest in technologies like the MicroCutter 5/80 that enable less invasive approaches to lobectomy that may accelerate the adoption of video-assisted thoracic surgery (VATS) techniques and other surgical procedures.”

MicroCutter Indication Information

The MicroCutter 5/80 Stapler is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine, and the transection of the appendix. The MicroCutter 5/80 may be used with both MicroCutter 30 White Reloads in vascular/thin tissue and MicroCutter 30 Blue Reloads for standard tissue.

About Dextera Surgical

Dextera Surgical (Nasdaq:DXTR) designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.

Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.

Forward-Looking Statements

The statements in this press release regarding Dextera Surgical’s expectations as to the benefits of using the MicroCutter 5/80 are “forward-looking statements.” There are a number of important factors that could cause Dextera Surgical’s results to differ materially from those indicated by these forward-looking statements, including the risks detailed from time to time in Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, under the caption “Risk Factors.” Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.